FY2025 · ended Dec 31, 2025 · Revenue $24.05M · Filed Mar 19, 2026
Alumis Inc. (ALMS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $24.1 million and a net loss of $243.3 million. Free cash flow was -$370.2 million. As of Jun 30, 2026 it held $63.7 million in cash and investments and $36.4 million in total debt.
Revenue (TTM)
$7.40M
Net income (TTM)
$-438.96M
-92.9% vs year-ago TTM
Operating cash flow (TTM)
$-351.40M
-1.8% vs year-ago TTM
Free cash flow (TTM)
$-351.80M
-1.4% vs year-ago TTM
EPS (TTM)
$-3.81
+0.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
—
Net cash
$27.28M
as of Jun 30, 2026
Operating margin
-6204.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALMS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1847367
- Former names
- FL2021-001, Inc. (until Mar 19, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $24.1M | — |
| Operating income | -$453.8M | -$300.8M |
| Net income | -$243.3M | -$294.2M |
| Diluted EPS | -$2.86 | -$10.38 |
| Operating cash flow | -$369.5M | -$255.1M |
| Free cash flow | -$370.2M | -$256.8M |
| Total assets | $411.9M | $341.0M |
| Total liabilities | $110.6M | $80.9M |
| Stockholders' equity | $301.3M | $260.1M |
| Cash and investments | $308.5M | $288.3M |
| Total debt | $36.9M | $30.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 29, 2026 | Jun 29, 2026 |
All 247 Alumis Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.